Seratrodast
Seratrodast
Seratrodast is a thromboxane receptor antagonist used primarily in the management of asthma. It functions by inhibiting the action of thromboxane A2, a compound that contributes to bronchoconstriction and inflammation in the airways. By blocking this receptor, seratrodast helps to alleviate the symptoms associated with asthma, such as wheezing and shortness of breath.
Pharmacology
Seratrodast is classified as a thromboxane receptor antagonist. Thromboxane A2 is a potent vasoconstrictor and pro-inflammatory mediator that plays a significant role in the pathophysiology of asthma. By antagonizing the thromboxane receptor, seratrodast reduces bronchoconstriction and inflammation, leading to improved airflow and reduced asthma symptoms.
Mechanism of Action
The primary mechanism of action of seratrodast involves the selective inhibition of the thromboxane A2 receptor. This inhibition prevents thromboxane A2 from binding to its receptor, thereby reducing the downstream effects of bronchoconstriction and inflammation. This action helps to maintain open airways and improve respiratory function in patients with asthma.
Clinical Use
Seratrodast is used in the treatment of asthma, particularly in patients who do not respond adequately to standard therapies such as inhaled corticosteroids and beta-agonists. It is often used as an adjunctive therapy to help control asthma symptoms and improve overall lung function.
Side Effects
Common side effects of seratrodast may include headache, dizziness, and gastrointestinal disturbances such as nausea and diarrhea. As with any medication, there is also the potential for allergic reactions, which should be monitored closely.
Synthesis
The synthesis of seratrodast involves several chemical reactions, starting from basic organic compounds. The process includes the formation of key intermediates that are subsequently modified to produce the final active pharmaceutical ingredient. The detailed steps of the synthesis are crucial for ensuring the purity and efficacy of the drug.
Related Pages
Transform your life with W8MD's budget GLP-1 injections from $125.
W8MD offers a medical weight loss program to lose weight in Philadelphia. Our physician-supervised medical weight loss provides:
- Most insurances accepted or discounted self-pay rates. We will obtain insurance prior authorizations if needed.
- Generic GLP1 weight loss injections from $125 for the starting dose.
- Also offer prescription weight loss medications including Phentermine, Qsymia, Diethylpropion, Contrave etc.
NYC weight loss doctor appointments
Start your NYC weight loss journey today at our NYC medical weight loss and Philadelphia medical weight loss clinics.
- Call 718-946-5500 to lose weight in NYC or for medical weight loss in Philadelphia 215-676-2334.
- Tags:NYC medical weight loss, Philadelphia lose weight Zepbound NYC, Budget GLP1 weight loss injections, Wegovy Philadelphia, Wegovy NYC, Philadelphia medical weight loss, Brookly weight loss and Wegovy NYC
WikiMD's Wellness Encyclopedia |
Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD